Sentinel node biopsy (SNB) plays a key role in assessing the prognosis of melanomas. In this fireside chat from our new SNB Training Program (Sentinel Node Biopsy: From guidelines to practice), MIA’s Prof Georgina Long AO, Prof John Thompson AO and A/Prof Sydney Ch’ng discuss:  the history of SNB in the management of melanoma its current role in the stratification of patients into those who may benefit from adjuvant therapies verses those for whom active surveillance is more appropriate other potential benefits of SNB, including the likelihood of SNB itself reducing the risk of nodal recurrence.  This podcast is suitable for Surgeons, Medical Oncologists, General Practitioners and other healthcare professionals.  SPEAKERS  A/Prof Sydney Ch’ng - Plastic &amp; Reconstructive Surgeon and Head &amp; Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Senior Surgeon, Melanoma Institute Australia   Please note that this podcast was accurate at the time of recording (July 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

Sentinel node biopsy (SNB) plays a key role in assessing the prognosis of melanomas. In this fireside chat from our new SNB Training Program (<a href="https://melanomaeducation.org.au/courses/melanoma201/" rel="noopener noreferer nofollow" target="_blank">Sentinel Node Biopsy: From guidelines to practice</a>), MIA’s Prof Georgina Long AO, Prof John Thompson AO and A/Prof Sydney Ch’ng discuss: <ul> <li>the history of SNB in the management of melanoma</li> <li>its current role in the stratification of patients into those who may benefit from adjuvant therapies verses those for whom active surveillance is more appropriate</li> <li>other potential benefits of SNB, including the likelihood of SNB itself reducing the risk of nodal recurrence.</li> </ul> This podcast is suitable for Surgeons, Medical Oncologists, General Practitioners and other healthcare professionals. SPEAKERS <ul> <li>A/Prof Sydney Ch’ng - Plastic &amp; Reconstructive Surgeon and Head &amp; Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney</li> <li>Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney</li> <li>Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Senior Surgeon, Melanoma Institute Australia</li> </ul> Please note that this podcast was accurate at the time of recording (July 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

When to recommend a sentinel node biopsy in melanoma

Our latest podcast explores the innovative approach of neoadjuvant  immunotherapy - administering checkpoint inhibitor immunotherapy before the surgical removal of  melanoma. This promising approach is creating a buzz among multidisciplinary clinicians and researchers globally as the potential  benefits for melanoma patients are being realised. Although neoadjuvant therapy is well established in oncology, using immunotherapy in melanoma has revolutionised patient outcomes through significant improvements in overall survival rates. In this engaging podcast, MIA’s Prof Georgina Long AO leads a discussion with multidisciplinary world leaders in the neoadjuvant space to discuss:  the benefits of checkpoint inhibitor immunotherapy the role of the pathologist in the assessment of neoadjuvant tissue the impact of surgical decision-making as neoadjuvant becomes mainstay treatment options for treatment-refractory patients the role of checkpoint inhibitor immunotherapy in non-melanoma skin cancer.  The discussion concludes with case studies to summarise key learnings. This podcast is suitable for Medical Oncologists, Oncologists,  Surgeons, Pathologists, Dermatologists, GPs, Oncology Nurses and other  healthcare professionals. SPEAKERS:  Prof Georgina Long AO - Co-Medical Director,  Melanoma Institute Australia | Chair, Melanoma Medical Oncology and  Translational Research, Melanoma Institute Australia and Royal North  Shore Hospital, The University of Sydney Prof Richard Scolyer AO - Co-Medical Director,  Melanoma Institute Australia | Pathologist, Melanoma Institute  Australia, Senior Staff Specialist, Royal Prince Alfred Hospital |  Clinical Professor, The University of Sydney A/Prof Alexander Menzies - Medical Oncologist,  Melanoma Institute Australia, Royal North Shore and Mater Hospitals |  Associate Professor of Melanoma Medical Oncology, The University of  Sydney A/Prof Alexander van Akkooi - Associate Professor  in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal  Prince Alfred Hospital, The University of Sydney  KEY CLINICAL TRIALS  SWOG PRADO OpACIN-neo NADINA  FURTHER EDUCATION  The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists   Please note that this podcast was accurate at the time of recording  (February 2023) but may not reflect the rapidly evolving treatment  landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Our latest podcast explores the innovative approach of neoadjuvant  immunotherapy - administering checkpoint inhibitor immunotherapy before the surgical removal of  melanoma. This promising approach is creating a buzz among multidisciplinary clinicians and researchers globally as the potential  benefits for melanoma patients are being realised. Although neoadjuvant therapy is well established in oncology, using immunotherapy in melanoma has revolutionised patient outcomes through significant improvements in overall survival rates. In this engaging podcast, MIA’s Prof Georgina Long AO leads a discussion with multidisciplinary world leaders in the neoadjuvant space to discuss: <ul> <li>the benefits of checkpoint inhibitor immunotherapy</li> <li>the role of the pathologist in the assessment of neoadjuvant tissue</li> <li>the impact of surgical decision-making as neoadjuvant becomes mainstay treatment</li> <li>options for treatment-refractory patients</li> <li>the role of checkpoint inhibitor immunotherapy in non-melanoma skin cancer.</li> </ul> The discussion concludes with case studies to summarise key learnings. This podcast is suitable for Medical Oncologists, Oncologists,  Surgeons, Pathologists, Dermatologists, GPs, Oncology Nurses and other  healthcare professionals. SPEAKERS: <ul> <li>Prof Georgina Long AO - Co-Medical Director,  Melanoma Institute Australia | Chair, Melanoma Medical Oncology and  Translational Research, Melanoma Institute Australia and Royal North  Shore Hospital, The University of Sydney</li> <li>Prof Richard Scolyer AO - Co-Medical Director,  Melanoma Institute Australia | Pathologist, Melanoma Institute  Australia, Senior Staff Specialist, Royal Prince Alfred Hospital |  Clinical Professor, The University of Sydney</li> <li>A/Prof Alexander Menzies - Medical Oncologist,  Melanoma Institute Australia, Royal North Shore and Mater Hospitals |  Associate Professor of Melanoma Medical Oncology, The University of  Sydney</li> <li>A/Prof Alexander van Akkooi - Associate Professor  in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal  Prince Alfred Hospital, The University of Sydney</li> </ul> KEY CLINICAL TRIALS <ol> <li><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2211437" rel="nofollow" target="_blank">SWOG</a></li> <li><a href="https://pubmed.ncbi.nlm.nih.gov/35661157/" rel="nofollow" target="_blank">PRADO</a></li> <li><a href="https://www.nature.com/articles/s41591-020-01211-7" rel="nofollow" target="_blank">OpACIN-neo</a></li> <li><a href="https://clinicaltrials.gov/ct2/show/NCT04949113" rel="nofollow" target="_blank">NADINA</a></li> </ol> FURTHER EDUCATION <ul> <li><a href="https://melanomaeducation.org.au/courses/melanoma177/" rel="nofollow" target="_blank">The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists </a></li> </ul> Please note that this podcast was accurate at the time of recording  (February 2023) but may not reflect the rapidly evolving treatment  landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Neoadjuvant immunotherapy: Revolutionising melanoma treatment

Lentigo maligna – a subtype of in situ melanoma – presents diagnostic and treatment challenges for clinicians. In this podcast, Dr Michael Rtshiladze leads a multidisciplinary  discussion to unravel our understanding of the pathology, diagnosis and  management of lentigo maligna, including:  clinical and histological presentation tools to diagnose and monitor lesions the impact of different types of biopsies the importance of mapping the extent of lesions the challenge of surgical management in cosmetically sensitive areas the role of radiation therapy and topical treatments when to refer your patient.  The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Plastic Surgeons, General Surgeons,  Dermatologists, Oncologists, Pathologists, GPs, Nurses and other  healthcare professionals. SPEAKERS  Dr Michael Rtshiladze - Plastic and Reconstructive  Surgeon, Melanoma Institute Australia, Royal Prince Alfred Hospital, The  Prince of Wales Hospital, St George Hospital and Sydney Children’s  Hospital Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Prof Pascale Guitera - Dermatologist, Melanoma  Institute Australia | Director, Sydney Melanoma Diagnostic Centre at  Royal Prince Alfred Hospital | Professorial Research Fellow, The  University of Sydney Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney  RESOURCE AND REFERENCE  Lentigo Maligna Patient Information Brochure Crouch G, Sinha S, Lo S, Saw RPM, Lee KK, Stretch J, Shannon K, Guitera P, Scolyer RA, Thompson JF &amp; Ch'ng S. Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. Eur J Surg Oncol. 2021 May;47(5):1145-1151.  Please note that this podcast was accurate at the time of recording  (December 2022) but may not reflect the rapidly evolving treatment  landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Lentigo maligna – a subtype of in situ melanoma – presents diagnostic and treatment challenges for clinicians. In this podcast, Dr Michael Rtshiladze leads a multidisciplinary  discussion to unravel our understanding of the pathology, diagnosis and  management of lentigo maligna, including: <ul> <li>clinical and histological presentation</li> <li>tools to diagnose and monitor lesions</li> <li>the impact of different types of biopsies</li> <li>the importance of mapping the extent of lesions</li> <li>the challenge of surgical management in cosmetically sensitive areas</li> <li>the role of radiation therapy and topical treatments</li> <li>when to refer your patient.</li> </ul> The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Plastic Surgeons, General Surgeons,  Dermatologists, Oncologists, Pathologists, GPs, Nurses and other  healthcare professionals. SPEAKERS <ul> <li>Dr Michael Rtshiladze - Plastic and Reconstructive  Surgeon, Melanoma Institute Australia, Royal Prince Alfred Hospital, The  Prince of Wales Hospital, St George Hospital and Sydney Children’s  Hospital</li> <li>Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital</li> <li>Prof Pascale Guitera - Dermatologist, Melanoma  Institute Australia | Director, Sydney Melanoma Diagnostic Centre at  Royal Prince Alfred Hospital | Professorial Research Fellow, The  University of Sydney</li> <li>Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney</li> </ul> RESOURCE AND REFERENCE <ul> <li><a href="https://melanomaeducation.org.au/product/lentigo-maligna-brochure/" rel="nofollow" target="_blank">Lentigo Maligna Patient Information Brochure</a></li> <li>Crouch G, Sinha S, Lo S, Saw RPM, Lee KK, Stretch J, Shannon K, Guitera P, Scolyer RA, Thompson JF &amp; Ch'ng S. <a href="https://pubmed.ncbi.nlm.nih.gov/33023795/" rel="nofollow" target="_blank">Clinical outcomes following surgical treatment of lentigo maligna of the head and neck.</a> Eur J Surg Oncol. 2021 May;47(5):1145-1151.</li> </ul> Please note that this podcast was accurate at the time of recording  (December 2022) but may not reflect the rapidly evolving treatment  landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Unravelling lentigo maligna

Despite recent advances in management of primary uveal melanoma, more than half of patients develop metastatic disease – often with poor outcomes. New therapeutic approaches to metastatic disease are vital. In this podcast, A/Prof Matteo Carlino interviews fellow Medical  Oncologist Prof Georgina Long AO and Ophthalmologist A/Prof Max Conway on our latest understanding of the diagnosis and management of early and advanced uveal melanoma, including:  presentation and diagnostic process current treatment options and rationale for local therapy in early melanoma determining which patients are suitable for screening for metastatic disease developing a surveillance plan based on risk of recurrence the different activity of systemic therapy in uveal versus cutaneous melanoma importance of the multidisciplinary team activity of tebentafusp in advanced uveal melanoma the current clinical trial landscape.  This podcast is suitable for Oncologists, Ophthalmologists, GPs, Oncology Nurses and other healthcare professionals. SPEAKERS  A/Prof Matteo Carlino - Medical Oncologist, Melanoma  Institute Australia, Westmead and Blacktown Hospitals Clinical  Associate Professor, The University of Sydney Prof Georgina Long AO - Co-Medical Director,  Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Max Conway - Ophthalmologist, Save Sight Institute, Sydney Eye Hospital and The University of Sydney  RESOURCES  Early Ocular Melanoma Patient Information Brochure Advanced Ocular Melanoma Patient Information Brochure Melanoma Education Portal  Please note that this podcast was accurate at the time of recording  (November 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS, Novartis and HEINE.

Despite recent advances in management of primary uveal melanoma, more than half of patients develop metastatic disease – often with poor outcomes. New therapeutic approaches to metastatic disease are vital. In this podcast, A/Prof Matteo Carlino interviews fellow Medical  Oncologist Prof Georgina Long AO and Ophthalmologist A/Prof Max Conway on our latest understanding of the diagnosis and management of early and advanced uveal melanoma, including: <ul> <li>presentation and diagnostic process</li> <li>current treatment options and rationale for local therapy in early melanoma</li> <li>determining which patients are suitable for screening for metastatic disease</li> <li>developing a surveillance plan based on risk of recurrence</li> <li>the different activity of systemic therapy in uveal versus cutaneous melanoma</li> <li>importance of the multidisciplinary team</li> <li>activity of tebentafusp in advanced uveal melanoma</li> <li>the current clinical trial landscape.</li> </ul> This podcast is suitable for Oncologists, Ophthalmologists, GPs, Oncology Nurses and other healthcare professionals. SPEAKERS <ul> <li>A/Prof Matteo Carlino - Medical Oncologist, Melanoma  Institute Australia, Westmead and Blacktown Hospitals Clinical  Associate Professor, The University of Sydney</li> <li>Prof Georgina Long AO - Co-Medical Director,  Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney</li> <li>A/Prof Max Conway - Ophthalmologist, Save Sight Institute, Sydney Eye Hospital and The University of Sydney</li> </ul> RESOURCES <ul> <li><a href="https://melanomaeducation.org.au/product/early-ocular-melanoma-brochure/" rel="nofollow" target="_blank">Early Ocular Melanoma Patient Information Brochure</a></li> <li><a href="https://melanomaeducation.org.au/product/advanced-ocular-melanoma-brochure/" rel="nofollow" target="_blank">Advanced Ocular Melanoma Patient Information Brochure</a></li> <li><a href="https://melanomaeducation.org.au/" rel="nofollow" target="_blank">Melanoma Education Portal</a></li> </ul> Please note that this podcast was accurate at the time of recording  (November 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS, Novartis and HEINE.

Diagnosis and management of uveal melanoma

Treating clinicians rely on pathology to help diagnose and stage their patient which fundamentally determines the treatment management  plan. Therefore, it is incredibly important to get it right in the first place. In this engaging podcast aimed at GPs, our multidisciplinary experts discuss:  Why can it be challenging to get the pathology right? What clinical information is important to include on the pathology request form? How is the pathology report structured? How is the specimen processed? What biopsy is key to maximising the diagnostic and prognostic interpretation of the pathology? Are partial biopsies ever appropriate? What implications does the type of biopsy have for subsequent surgery? When does a GP need to refer their patient?  The discussion is concluded with two case studies to summarise key learnings. This podcast is suitable for GPs, Dermatologists, Surgeons, Oncologists, Pathologists and other healthcare professionals. SPEAKERS  Dr Adrian Quek - Skin Cancer GP, Melanoma Institute Australia and The Chatswood Skin Cancer Clinic Dr Alison Potter - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Dr Nigel Maher - McMurtrie Cancer Pathology Fellow, Melanoma Institute Australia A/Prof Alexander van Akkooi - Associate Professor  in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney Dr Niamh-Anna O’Sullivan - Specialist Dermatologist, Melanoma Institute Australia  HOST  Danielle Fischer - Education Program Manager, Melanoma Institute Australia  Please note that this podcast was accurate at the time of recording (June 2022) but may not reflect the rapidly evolving treatment landscape  and approvals in Australia. For more practice-changing education, visit our Melanoma Education Portal. MIA's Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

Treating clinicians rely on pathology to help diagnose and stage their patient which fundamentally determines the treatment management  plan. Therefore, it is incredibly important to get it right in the first place. In this engaging podcast aimed at GPs, our multidisciplinary experts discuss: <ul> <li>Why can it be challenging to get the pathology right?</li> <li>What clinical information is important to include on the pathology request form?</li> <li>How is the pathology report structured?</li> <li>How is the specimen processed?</li> <li>What biopsy is key to maximising the diagnostic and prognostic interpretation of the pathology?</li> <li>Are partial biopsies ever appropriate?</li> <li>What implications does the type of biopsy have for subsequent surgery?</li> <li>When does a GP need to refer their patient?</li> </ul> The discussion is concluded with two case studies to summarise key learnings. This podcast is suitable for GPs, Dermatologists, Surgeons, Oncologists, Pathologists and other healthcare professionals. SPEAKERS <ul> <li>Dr Adrian Quek - Skin Cancer GP, Melanoma Institute Australia and The Chatswood Skin Cancer Clinic</li> <li>Dr Alison Potter - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital</li> <li>Dr Nigel Maher - McMurtrie Cancer Pathology Fellow, Melanoma Institute Australia</li> <li>A/Prof Alexander van Akkooi - Associate Professor  in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney</li> <li>Dr Niamh-Anna O’Sullivan - Specialist Dermatologist, Melanoma Institute Australia</li> </ul> HOST <ul> <li>Danielle Fischer - Education Program Manager, Melanoma Institute Australia</li> </ul> Please note that this podcast was accurate at the time of recording (June 2022) but may not reflect the rapidly evolving treatment landscape  and approvals in Australia. For more practice-changing education, visit our <a href="https://melanomaeducation.org.au/" rel="nofollow" target="_blank">Melanoma Education Portal</a>. MIA's Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

Getting the pathology right: Melanoma in General Practice

The role of pathology in the diagnosis and treatment of melanoma is pivotal to optimal patient care. With so many disciplines relying on the pathologist for accurate diagnoses and critical pathological information, we decided to reach out to our clinical melanoma community to ask them for their critical pathology questions.  In this podcast, Prof John Thompson AO and Prof Fergal Moloney pick at the brain of the world's leading melanoma Pathologist, Prof Richard Scolyer AO, as they discuss:   The clinical information needed to aid diagnosis  The role of artificial intelligence and computing in pathology  Overdiagnosis of melanoma  The problem of partial biopsies  Diagnosing borderline lesions  What is a melanocytoma and how should it be managed  What is an irritated naevus  Dysplastic naevi and appropriate management   This podcast is suitable for GPs, Dermatologists, Surgeons, Oncologists, Pathologists and other healthcare professionals.  SPEAKERS  Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney  Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Member, Melanoma Institute Australia  Prof Fergal Moloney - Consultant Dermatologist, Melanoma Institute Australia and Mater Misericordiae University Hospital | Clinical Professor, University College, Dublin  Please note that this podcast was accurate at the time of recording (June 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.  For more practice-changing education, visit our Melanoma Education Portal.  MIA's Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

The role of pathology in the diagnosis and treatment of melanoma is pivotal to optimal patient care. With so many disciplines relying on the pathologist for accurate diagnoses and critical pathological information, we decided to reach out to our clinical melanoma community to ask them for their critical pathology questions.  In this podcast, Prof John Thompson AO and Prof Fergal Moloney pick at the brain of the world's leading melanoma Pathologist, Prof Richard Scolyer AO, as they discuss:  <ul> <li>The clinical information needed to aid diagnosis </li> <li>The role of artificial intelligence and computing in pathology </li> <li>Overdiagnosis of melanoma </li> <li>The problem of partial biopsies </li> <li>Diagnosing borderline lesions </li> <li>What is a melanocytoma and how should it be managed </li> <li>What is an irritated naevus </li> <li>Dysplastic naevi and appropriate management </li> </ul> This podcast is suitable for GPs, Dermatologists, Surgeons, Oncologists, Pathologists and other healthcare professionals.  SPEAKERS  Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney  Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Member, Melanoma Institute Australia  Prof Fergal Moloney - Consultant Dermatologist, Melanoma Institute Australia and Mater Misericordiae University Hospital | Clinical Professor, University College, Dublin  Please note that this podcast was accurate at the time of recording (June 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.  For more practice-changing education, visit our Melanoma Education Portal.  MIA's Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

Critical questions for a melanoma pathologist

Cancer drugs have rapidly evolved in the last decade. Alongside the significant benefits are new toxicity profiles that clinicians need to be aware of and manage. In this podcast, A/Prof Carlino interviews fellow Medical Oncologist Prof Georgina Long AO on the adverse events/toxicities associated with targeted therapies (combination BRAF/MEK inhibitors) and immunotherapies (anti-PD-1, anti-LAG-3 and anti-CTLA-4), particularly in melanoma, and how they should be managed. This podcast is suitable for Oncologists, Emergency Medicine Physicians, GPs, Oncology Nurses and other healthcare professionals. SPEAKERS  Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals Clinical Associate Professor, The University of Sydney  Please note that this podcast was accurate at the time of recording (May 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

Cancer drugs have rapidly evolved in the last decade. Alongside the significant benefits are new toxicity profiles that clinicians need to be aware of and manage. In this podcast, A/Prof Carlino interviews fellow Medical Oncologist Prof Georgina Long AO on the adverse events/toxicities associated with targeted therapies (combination BRAF/MEK inhibitors) and immunotherapies (anti-PD-1, anti-LAG-3 and anti-CTLA-4), particularly in melanoma, and how they should be managed. This podcast is suitable for Oncologists, Emergency Medicine Physicians, GPs, Oncology Nurses and other healthcare professionals. SPEAKERS <ul> <li>Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney</li> <li>A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals Clinical Associate Professor, The University of Sydney</li> </ul> Please note that this podcast was accurate at the time of recording (May 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

Toxicity management in melanoma

The field of melanoma has experienced a paradigm shift in recent years, with advancements in both diagnosis and management driving improved patient outcomes. Through the power of research, day-to-day practice continues to be transformed.  In this lively podcast, two of Australia's leading melanoma experts Prof Richard Scolyer AO and Prof Georgina Long AO discuss:   how melanoma management has transformed in the last decade  the challenge of diagnosing melanoma for clinicians and pathologists, and practical ways to help make accurate assessments  the importance of staging  why sentinel node biopsies are important  how multidisciplinary care enhances patient outcomes  emerging evidence on neoadjuvant treatment and how this will change the way melanoma is managed  the challenge of supportive care and where to find help.   In this practical discussion, resources and further education for deeper dives into specific topics are also mentioned, with links below.  This podcast is suitable for oncologists, surgeons, dermatologists, skin cancer GPs, GPs, nurses and other healthcare professionals.  SPEAKERS   Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney  Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney   LINKS TO RESOURCES   Melanoma Risk Prediction Tools  Prof John Thompson's presentation: Update on melanoma staging  Order or download a pocket-sized Melanoma Staging Card  Prof Richard Scolyer's presentation: Melanoma near misses: Clues to diagnosis  Dermoscopy module: Techniques in melanoma assessment  Interactive game: DermChallenge: Management.  Debate: To shave or not to shave when biopsying melanoma  Podcast: Multidisciplinary management of primary melanoma  Presentation by Dr Rob Rawson and Dr Michael Rtshiladze: The melanoma pathology report and its impact on clinical management  Wiki melanoma guidelines: Clinical practice guidelines for the diagnosis and management of melanoma  Interactive module: The current role of sentinel node biopsy in the management of melanoma  Debate: The role of sentinel node biopsy is overstated in melanoma  SNB Melanoma Risk Calculator   Visit the Melanoma Education Portal for the full list of resources.

The field of melanoma has experienced a paradigm shift in recent years, with advancements in both diagnosis and management driving improved patient outcomes. Through the power of research, day-to-day practice continues to be transformed.  In this lively podcast, two of Australia's leading melanoma experts Prof Richard Scolyer AO and Prof Georgina Long AO discuss:  <ul> <li>how melanoma management has transformed in the last decade </li> <li>the challenge of diagnosing melanoma for clinicians and pathologists, and practical ways to help make accurate assessments </li> <li>the importance of staging </li> <li>why sentinel node biopsies are important </li> <li>how multidisciplinary care enhances patient outcomes </li> <li>emerging evidence on neoadjuvant treatment and how this will change the way melanoma is managed </li> <li>the challenge of supportive care and where to find help. </li> </ul> In this practical discussion, resources and further education for deeper dives into specific topics are also mentioned, with links below.  This podcast is suitable for oncologists, surgeons, dermatologists, skin cancer GPs, GPs, nurses and other healthcare professionals.  SPEAKERS  <ul> <li>Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney </li> <li>Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney </li> </ul> LINKS TO RESOURCES  <ul> <li><a href="https://www.melanomarisk.org.au/" rel="nofollow" target="_blank">Melanoma Risk Prediction Tools </a></li> <li>Prof John Thompson's presentation: <a href="https://melanomaeducation.org.au/courses/melanoma112/" rel="nofollow" target="_blank">Update on melanoma staging </a></li> <li>Order or download a pocket-sized <a href="https://melanomaeducation.org.au/portfolio/melanoma_staging_cards/" rel="nofollow" target="_blank">Melanoma Staging Card </a></li> <li>Prof Richard Scolyer's presentation: <a href="https://melanomaeducation.org.au/courses/melanoma109/" rel="nofollow" target="_blank">Melanoma near misses: Clues to diagnosis </a></li> <li>Dermoscopy module: <a href="https://melanomaeducation.org.au/courses/melanoma104/" rel="nofollow" target="_blank">Techniques in melanoma assessment</a> </li> <li>Interactive game: <a href="https://melanomaeducation.org.au/courses/melanoma108/" rel="nofollow" target="_blank">DermChallenge: Management</a>. </li> <li>Debate: <a href="https://melanomaeducation.org.au/courses/melanoma134/" rel="nofollow" target="_blank">To shave or not to shave when biopsying melanoma</a> </li> <li>Podcast: <a href="https://melanomaeducation.org.au/courses/melanoma122/" rel="nofollow" target="_blank">Multidisciplinary management of primary melanoma</a> </li> <li>Presentation by Dr Rob Rawson and Dr Michael Rtshiladze: <a href="https://melanomaeducation.org.au/courses/melanoma124/" rel="nofollow" target="_blank">The melanoma pathology report and its impact on clinical management </a></li> <li>Wiki melanoma guidelines: <a href="https://wiki.cancer.org.au/australia/Guidelines:Melanoma" rel="nofollow" target="_blank">Clinical practice guidelines for the diagnosis and management of melanoma</a> </li> <li>Interactive module: <a href="https://melanomaeducation.org.au/courses/melanoma127/" rel="nofollow" target="_blank">The current role of sentinel node biopsy in the management of melanoma </a></li> <li>Debate: The role of sentinel node biopsy is overstated in melanoma </li> <li><a href="https://www.melanomarisk.org.au/SNLLand" rel="nofollow" target="_blank">SNB Melanoma Risk Calculator </a></li> </ul> Visit the Melanoma Education Portal for the full list of resources.

The evolving paradigm shift in melanoma

Managing in-transit melanoma can be challenging, and it presents and progresses as a heterogeneous disease. Multidisciplinary care is recommended for this complex disease to determine the optimal outcome for the patient.  In this engaging podcast, our multidisciplinary expert panel - featuring a Dermatologist, Surgeon and Medical Oncologist - discuss:   the clinical presentation of in-transit melanoma  importance of biopsy and imaging  local therapy options including surgical resection, topical diphencyprone, radiotherapy, injectable agents and isolated limb infusion systemic therapy options in the adjuvant and unresectable settings.   In addition, the panel reviews a case study to put learnings into practice.  This podcast is suitable for Surgeons, Medical Oncologists, Dermatologists, Skin Cancer GPs, GPs, Nurses and other healthcare professionals.  Please note that this podcast was accurate at the time of recording (October 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.  SPEAKERS   A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney  A/Prof Robyn Saw - General Surgeon, Melanoma Institute Australia | Associate Professor in Surgery, The University of Sydney | Head of Department, Melanoma and Surgical Oncology, Royal Prince Alfred Hospital  Prof Diona Damian - Professor of Dermatology, The University of Sydney | Clinical Academic, Royal Prince Alfred Hospital |Associate, Melanoma Institute Australia

Managing in-transit melanoma can be challenging, and it presents and progresses as a heterogeneous disease. Multidisciplinary care is recommended for this complex disease to determine the optimal outcome for the patient.  In this engaging podcast, our multidisciplinary expert panel - featuring a Dermatologist, Surgeon and Medical Oncologist - discuss:  <ul> <li>the clinical presentation of in-transit melanoma </li> <li>importance of biopsy and imaging </li> <li>local therapy options including surgical resection, topical diphencyprone, radiotherapy, injectable agents and isolated limb infusion</li> <li>systemic therapy options in the adjuvant and unresectable settings. </li> </ul> In addition, the panel reviews a case study to put learnings into practice.  This podcast is suitable for Surgeons, Medical Oncologists, Dermatologists, Skin Cancer GPs, GPs, Nurses and other healthcare professionals.  Please note that this podcast was accurate at the time of recording (October 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.  SPEAKERS  <ul> <li>A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney </li> <li>A/Prof Robyn Saw - General Surgeon, Melanoma Institute Australia | Associate Professor in Surgery, The University of Sydney | Head of Department, Melanoma and Surgical Oncology, Royal Prince Alfred Hospital </li> <li>Prof Diona Damian - Professor of Dermatology, The University of Sydney | Clinical Academic, Royal Prince Alfred Hospital |Associate, Melanoma Institute Australia</li></ul>

Multidisciplinary management of in-transit melanoma

Melanoma has many mimics, making detection a challenge. However, early detection and appropriate management of melanoma is crucial to ensuring a patient has the best chance of survival.

Multidisciplinary management of primary melanoma

Melanoma Insights for Professionals features interviews with leading melanoma specialists who translate the latest research and best practice into the everyday clinic setting. Developed by Melanoma Institute Australia, this series is for multidisciplinary healthcare professionals who want to be across the latest developments in melanoma. For more education, visit melanomaeducation.org.au.

Due to the highly aggressive nature of Merkel cell carcinoma, accurate and timely diagnosis is essential to ensure optimal management. Although our understanding of the biology of the disease has advanced significantly in recent years, a clinical conundrum still exists regarding the ideal therapeutic strategy for each patient.  In this podcast, our multidisciplinary panel discuss:   the pathology of Merkel cell carcinoma  differential diagnoses  clinical presentation  the role of surgery and its importance in diagnosis, staging and salvage  how radiotherapy is used in the definitive and adjuvant settings  the role of systemic therapy  emerging therapies and the importance of clinical trials.   In addition, the panel reviews two case studies to put learnings into practice.  This podcast is suitable for Medical Oncologists, Surgeons, Dermatologists, GPs, Nurses and other healthcare professionals.  Please note that this podcast was accurate at the time of recording (March 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.  SPEAKERS:   Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital  Dr Kerwin Shannon - Surgical Oncologist and Head and Neck Surgeon, Melanoma Institute Australia and Chris O'Brien Lifehouse  Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia |Clinical Professor, The University of Sydney  Dr Ines Silva - Medical Oncologist and Researcher, Melanoma Institute Australia | Fellow, Westmead Hospital

Due to the highly aggressive nature of Merkel cell carcinoma, accurate and timely diagnosis is essential to ensure optimal management. Although our understanding of the biology of the disease has advanced significantly in recent years, a clinical conundrum still exists regarding the ideal therapeutic strategy for each patient.  In this podcast, our multidisciplinary panel discuss:  <ul> <li>the pathology of Merkel cell carcinoma </li> <li>differential diagnoses </li> <li>clinical presentation </li> <li>the role of surgery and its importance in diagnosis, staging and salvage </li> <li>how radiotherapy is used in the definitive and adjuvant settings </li> <li>the role of systemic therapy </li> <li>emerging therapies and the importance of clinical trials. </li> </ul> In addition, the panel reviews two case studies to put learnings into practice.  This podcast is suitable for Medical Oncologists, Surgeons, Dermatologists, GPs, Nurses and other healthcare professionals.  Please note that this podcast was accurate at the time of recording (March 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.  SPEAKERS:  <ul> <li>Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital </li> <li>Dr Kerwin Shannon - Surgical Oncologist and Head and Neck Surgeon, Melanoma Institute Australia and Chris O'Brien Lifehouse </li> <li>Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia |Clinical Professor, The University of Sydney </li> <li>Dr Ines Silva - Medical Oncologist and Researcher, Melanoma Institute Australia | Fellow, Westmead Hospital</li></ul>

Multidisciplinary management of Merkel cell carcinoma

Hear our expert multidisciplinary panel discuss the latest management options for the treatment of squamous cell carcinoma and basal cell carcinoma - the most common forms of non-melanoma skin cancers. They have a wide clinical and pathological presentation, and early detection and treatment is vital to reduce the morbidity and mortality associated with these diseases. In this podcast, our multidisciplinary panel discuss:  the pathology and aetiology of SCCs and BCCs when a GP should refer their patient the role of surgery when radiotherapy is indicated in the definitive and adjuvant setting how systemic therapy can play a role in advanced disease.  In addition, the panel review two cases to solidify the learnings. This podcast is suitable for Medical Oncologists, Surgeons, Dermatologists, GPs, Nurses and other healthcare professionals. Please note that this podcast was accurate at the time of recording (March 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. SPEAKERS: Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Dr Kerwin Shannon - Surgical Oncologist and Head and Neck Surgeon, Melanoma Institute Australia and Chris O’Brien Lifehouse Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia |Clinical Professor, The University of Sydney Dr Ines Silva - Medical Oncologist and Researcher, Melanoma Institute Australia | Fellow, Westmead Hospital

Hear our expert multidisciplinary panel discuss the latest management options for the treatment of squamous cell carcinoma and basal cell carcinoma - the most common forms of non-melanoma skin cancers. They have a wide clinical and pathological presentation, and early detection and treatment is vital to reduce the morbidity and mortality associated with these diseases. In this podcast, our multidisciplinary panel discuss: <ul> <li>the pathology and aetiology of SCCs and BCCs</li> <li>when a GP should refer their patient</li> <li>the role of surgery</li> <li>when radiotherapy is indicated in the definitive and adjuvant setting</li> <li>how systemic therapy can play a role in advanced disease.</li> </ul> In addition, the panel review two cases to solidify the learnings. This podcast is suitable for Medical Oncologists, Surgeons, Dermatologists, GPs, Nurses and other healthcare professionals. Please note that this podcast was accurate at the time of recording (March 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. SPEAKERS: Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Dr Kerwin Shannon - Surgical Oncologist and Head and Neck Surgeon, Melanoma Institute Australia and Chris O’Brien Lifehouse Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia |Clinical Professor, The University of Sydney Dr Ines Silva - Medical Oncologist and Researcher, Melanoma Institute Australia | Fellow, Westmead Hospital

Multidisciplinary management of SCC and BCC

The success of immunotherapy and targeted therapy in the treatment of advanced melanoma has led to the same therapies being used in the adjuvant setting to reduce the risk of recurrence.  In this podcast, A/Prof Matteo Carlino interviews fellow Medical Oncologist A/Prof Alexander Menzies on the evidence for adjuvant therapy to guide clinical decision-making. Understanding the complexities of adjuvant therapy is key to identifying and managing patients suitable for this treatment. Topics covered in this discussion include:  Weighing up the risk-benefit ratio in the use of adjuvant therapy  Patient populations who are not suitable for adjuvant therapy  Treating BRAF-mutant patients - which option is best?  Adjuvant treatment for mucosal melanoma  Follow-up imaging after adjuvant therapy to identify recurrence and toxicities  The diminished role of completion lymph node dissection The role of adjuvant radiotherapy  Adjuvant therapy in Stage II melanoma  Neoadjuvant therapy  Management of recurrences on or after adjuvant therapy   This podcast is suitable for Oncologists, Oncology Nurses and other healthcare professionals.  Please note that this podcast was accurate at the time of recording (Feb 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.  SPEAKERS:   A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia, Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney  A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals Clinical Associate Professor, The University of Sydney

The success of immunotherapy and targeted therapy in the treatment of advanced melanoma has led to the same therapies being used in the adjuvant setting to reduce the risk of recurrence.  In this podcast, A/Prof Matteo Carlino interviews fellow Medical Oncologist A/Prof Alexander Menzies on the evidence for adjuvant therapy to guide clinical decision-making. Understanding the complexities of adjuvant therapy is key to identifying and managing patients suitable for this treatment. Topics covered in this discussion include: <ul> <li>Weighing up the risk-benefit ratio in the use of adjuvant therapy </li> <li>Patient populations who are not suitable for adjuvant therapy </li> <li>Treating BRAF-mutant patients - which option is best? </li> <li>Adjuvant treatment for mucosal melanoma </li> <li>Follow-up imaging after adjuvant therapy to identify recurrence and toxicities </li> <li>The diminished role of completion lymph node dissection</li> <li>The role of adjuvant radiotherapy </li> <li>Adjuvant therapy in Stage II melanoma </li> <li>Neoadjuvant therapy </li> <li>Management of recurrences on or after adjuvant therapy </li> </ul> This podcast is suitable for Oncologists, Oncology Nurses and other healthcare professionals.  Please note that this podcast was accurate at the time of recording (Feb 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.  SPEAKERS:  <ul> <li>A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia, Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney </li> <li>A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals Clinical Associate Professor, The University of Sydney</li></ul>

The complexities of adjuvant therapy in melanoma

In the rapidly evolving treatment landscape for advanced melanoma, medical oncologists now have a suite of treatments to choose from for their patients. In this engaging podcast, A/Prof Menzies interviews fellow Medical Oncologist A/Prof Carlino on the rationale behind their clinical decision making when it comes to choosing the most appropriate therapy for their patients, including sequencing and combination therapies. They also take a deeper dive into treatment toxicities and how to manage them for targeted and immune therapies.  This podcast is suitable for Oncologists, Oncology Nurses and other healthcare professionals. Please note that this podcast was accurate at the time of recording (June 2020) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

In the rapidly evolving treatment landscape for advanced melanoma, medical oncologists now have a suite of treatments to choose from for their patients. In this engaging podcast, A/Prof Menzies interviews fellow Medical Oncologist A/Prof Carlino on the rationale behind their clinical decision making when it comes to choosing the most appropriate therapy for their patients, including sequencing and combination therapies. They also take a deeper dive into treatment toxicities and how to manage them for targeted and immune therapies.  This podcast is suitable for Oncologists, Oncology Nurses and other healthcare professionals. Please note that this podcast was accurate at the time of recording (June 2020) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

Emerging therapies in advanced melanoma in 2020

Melanoma is one of the most common human malignancies, however we often don't often think of it as a disease that occurs in children. Although exceedingly rare, clinicians do need to be aware of paediatric melanoma and have a high level of suspicion for these lesions as they are often diagnosed late.  In this podcast, a Surgeon, Dermatologist and Medical Oncologist discuss how melanoma presents in children and adolescents, and how this differs from the adult setting. They also discuss how melanoma should be managed in these patients and discuss two patient case studies.  This podcast is suitable for Surgeons, Dermatologists, Medical Oncologists, GPs and other healthcare professionals. SPEAKERS  A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney Dr Gideon Sandler - Consultant Adult and Paediatric Head and Neck Surgeon and Surgical Oncologist, Westmead Hospital and the Children’s Hospital at Westmead Affiliate, Melanoma Institute Australia Dr Li-Chuen Wong - Consultant Paediatric and Adult Dermatologist and Head of Dermatology | Children’s Hospital at Westmead

Melanoma is one of the most common human malignancies, however we often don't often think of it as a disease that occurs in children. Although exceedingly rare, clinicians do need to be aware of paediatric melanoma and have a high level of suspicion for these lesions as they are often diagnosed late.  In this podcast, a Surgeon, Dermatologist and Medical Oncologist discuss how melanoma presents in children and adolescents, and how this differs from the adult setting. They also discuss how melanoma should be managed in these patients and discuss two patient case studies.  This podcast is suitable for Surgeons, Dermatologists, Medical Oncologists, GPs and other healthcare professionals. SPEAKERS <ul> <li>A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney</li> <li>Dr Gideon Sandler - Consultant Adult and Paediatric Head and Neck Surgeon and Surgical Oncologist, Westmead Hospital and the Children’s Hospital at Westmead Affiliate, Melanoma Institute Australia</li> <li>Dr Li-Chuen Wong - Consultant Paediatric and Adult Dermatologist and Head of Dermatology | Children’s Hospital at Westmead</li></ul>

Melanoma in children and adolescents

In the evolving treatment landscape of melanoma, it is important for GPs and Dermatologists to be confident in managing or knowing when to refer their melanoma patients. In this podcast, Surgeon A/Prof Robyn Saw, Dermatologist Dr Annika Smith and Skin Cancer GP Dr Adrian Quek discuss the ideal biopsy for a melanoma diagnosis, provides an overview of management of early stage disease, outlines the role of sentinel lymph node biopsy and discusses which patients need referral to a specialist melanoma clinic.

When should I refer to a melanoma clinic?

In the last decade, the treatment landscape for melanoma has been transformative for patients with advanced disease. Although managed primarily by medical oncologists, it is important for GPs to be across which treatments are available for their patients as they are often the first point of contact when a patient becomes unwell.  In this podcast, Medical Oncologist Professor Georgina Long discusses how systemic therapy is used in the treatment of advanced melanoma, and how a GP can identify and manage toxicities in patients being treated with targeted or immunotherapies.  This podcast is suitable for GPs, Skin Cancer GPs, nurses and other healthcare professionals. Please note that this podcast was accurate at the time of recording (Oct 2019) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

In the last decade, the treatment landscape for melanoma has been transformative for patients with advanced disease. Although managed primarily by medical oncologists, it is important for GPs to be across which treatments are available for their patients as they are often the first point of contact when a patient becomes unwell.  In this podcast, Medical Oncologist Professor Georgina Long discusses how systemic therapy is used in the treatment of advanced melanoma, and how a GP can identify and manage toxicities in patients being treated with targeted or immunotherapies.  This podcast is suitable for GPs, Skin Cancer GPs, nurses and other healthcare professionals. Please note that this podcast was accurate at the time of recording (Oct 2019) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

What GPs need to know about melanoma patients on systemic therapies

Thanks to advancements in therapy, we are now seeing large numbers of patients surviving advanced melanoma, and with that comes well-being and psychological challenges that need to be addressed. Clinicians need to be cognisant of their patients' needs beyond the medical side.Dietitian Jane Freeman, Psychologist Michelle Davey and Physiotherapist Carol Morris discuss the role that food, mood and movement has in the holistic approach to treating melanoma patients and survivors, and the role that you - as a clinician - can play.This podcast is suitable for oncologists, GPs, oncology nurses and other healthcare practitioners.

Thanks to advancements in therapy, we are now seeing large numbers of patients surviving advanced melanoma, and with that comes well-being and psychological challenges that need to be addressed. Clinicians need to be cognisant of their patients' needs beyond the medical side. Dietitian Jane Freeman, Psychologist Michelle Davey and Physiotherapist Carol Morris discuss the role that food, mood and movement has in the holistic approach to treating melanoma patients and survivors, and the role that you - as a clinician - can play. This podcast is suitable for oncologists, GPs, oncology nurses and other healthcare practitioners.

Food, Mood and Move in Melanoma

The management of melanoma patients with brain metastases has changed rapidly in the last five years, and patients now have much-improved survival rates. Brain metastases are no longer a death sentence and many people can have control of their disease with quality life.In this podcast, Medical Oncologist A/Prof Alex Menzies, Neurosurgeon Dr Brindha Shivalingam and Radiation Oncologist Prof Angela Hong discuss the contemporary multidisciplinary management of patients with brain metastases and through examining two case studies, they discern the factors that need to be considered for deciding best practice.This podcast is suitable for medical oncologists, rural oncologists, radiation oncologists, surgeons (including neurosurgeons), and may also be of interest to GPs, oncology nurses and other healthcare practitioners.

The management of melanoma patients with brain metastases has changed rapidly in the last five years, and patients now have much-improved survival rates. Brain metastases are no longer a death sentence and many people can have control of their disease with quality life. In this podcast, Medical Oncologist A/Prof Alex Menzies, Neurosurgeon Dr Brindha Shivalingam and Radiation Oncologist Prof Angela Hong discuss the contemporary multidisciplinary management of patients with brain metastases and through examining two case studies, they discern the factors that need to be considered for deciding best practice. This podcast is suitable for medical oncologists, rural oncologists, radiation oncologists, surgeons (including neurosurgeons), and may also be of interest to GPs, oncology nurses and other healthcare practitioners.

Management of Brain Metastases in Melanoma

Melanoma Insights for Professionals features interviews with leading melanoma specialists who translate the latest research and best practice into the everyday clinic setting. Developed by Melanoma Institute Australia, this series is for multidisciplinary healthcare professionals who want to be across the latest developments in melanoma. For more education, visit <a href="http://melanomaeducation.org.au" rel="nofollow" target="_blank">melanomaeducation.org.au</a>.

Melanoma Insights for Professionals

The best podcast episodes on romantic relationships. Episodes talk about the 5 love languages, intimacy, and the taboo topics of sexual desires and infidelity. This topic is a deep dive into the science and complexities that face us in our relationships with others. Add episodes you're interested into your queue below!

Best Episodes on Relationships & Love

The Best Multi-Part Documentaries, with documentaries on Obama, Federer vs Nadal, the making of Star Wars, Netflix vs Blockbuster and more. Add episodes you're interested into your queue below!